AQST Stock Overview
Operates as a pharmaceutical company in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Aquestive Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.43 |
| 52 Week High | US$6.23 |
| 52 Week Low | US$1.25 |
| Beta | 2.79 |
| 11 Month Change | 28.46% |
| 3 Month Change | 4.89% |
| 1 Year Change | 76.80% |
| 33 Year Change | -12.72% |
| 5 Year Change | -9.97% |
| Change since IPO | -78.63% |
Recent News & Updates
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Recent updates
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Aug 11What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Jul 24Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
May 22Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Apr 09Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Feb 28Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Jan 19Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
Jan 05Aquestive Therapeutics, Inc. (NASDAQ:AQST) Surges 63% Yet Its Low P/S Is No Reason For Excitement
Apr 17Aquestive Therapeutics receives positive FDA response for AQST-109 epinephrine for severe allergic reaction
Oct 11Aquestive Therapeutics, Pharmanovia ink licensing & supply pact for Libervant buccal film
Sep 28Aquestive Therapeutics: FDA Stymies Libervant Launch
Sep 05Aquestive Therapeutics: A First Take
Aug 29Shareholder Returns
| AQST | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.3% | 2.8% | 0.2% |
| 1Y | 76.8% | 14.4% | 17.6% |
Return vs Industry: AQST exceeded the US Pharmaceuticals industry which returned 14.4% over the past year.
Return vs Market: AQST exceeded the US Market which returned 17.6% over the past year.
Price Volatility
| AQST volatility | |
|---|---|
| AQST Average Weekly Movement | 9.3% |
| Pharmaceuticals Industry Average Movement | 9.2% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 14.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: AQST's share price has been volatile over the past 3 months.
Volatility Over Time: AQST's weekly volatility (9%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 135 | Dan Barber | www.aquestive.com |
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson’s disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis.
Aquestive Therapeutics, Inc. Fundamentals Summary
| AQST fundamental statistics | |
|---|---|
| Market cap | US$312.33m |
| Earnings (TTM) | -US$25.72m |
| Revenue (TTM) | US$58.36m |
5.4x
P/S Ratio-12.1x
P/E RatioIs AQST overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AQST income statement (TTM) | |
|---|---|
| Revenue | US$58.36m |
| Cost of Revenue | US$18.39m |
| Gross Profit | US$39.97m |
| Other Expenses | US$65.69m |
| Earnings | -US$25.72m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.28 |
| Gross Margin | 68.49% |
| Net Profit Margin | -44.07% |
| Debt/Equity Ratio | -84.2% |
How did AQST perform over the long term?
See historical performance and comparison